Mike Zaman's  Instablog

Mike Zaman
Send Message
  • Antares Pharma (ATRS) QuickShot Auto Injector Positive Data, PowerSecure (POWR) $20M In New Business 0 comments
    Feb 20, 2014 8:56 AM | about stocks: ATRS, POWR

    http://static.cdn-seekingalpha.com/uploads/2014/2/20/saupload_atrs.jpg Antares Pharma Inc. (NASDAQ:ATRS)

    Male hypogonadism is a condition in which the body doesn't produce enough testosterone - the hormone that plays a key role in masculine growth and development during puberty - or has an impaired ability to produce sperm or both.

    Hypogonadism in men causes a constellation of signs and symptoms that may include decreased libido, erectile dysfunction, decreased volume of ejaculate, loss of body and facial hair, weakness, decreased bone density, decreased lean body mass, increased body fat, fatigue and anaemia.

    The prevalence of hypogonadism (low testosterone) increases with age. Researchers have found that the incidence of low testosterone increases from approximately 20% of men over 60, to 30% of men over 70 and 50% of men over 80 years of age.

    Hypogonadism in adult men is often overlooked, even in the presence of associated symptoms, because hypogonadal men often ignore their symptoms or attribute them to alternate causes, including ageing

    ATRS reported positive results from a multi-center phase 2 clinical study evaluating the pharmacokinetic profile of testosterone enanthate administered once-weekly by subcutaneous injection at doses of 50 mg and 100 mg using the VIBEX QuickShot auto injector in testosterone deficient adult males.

    According to ATRS, the administration of testosterone using the company's proprietary QuickShot device showed that normal testosterone levels can be rapidly restored and then reliably maintained with reduced peak to trough fluctuations relative to those associated with intramuscular injections.

    Unlike topical treatments for males with hypogonadism, currently approved injectable forms of testosterone do not carry a black box warning for risk of transference, which has been reported to lead to abnormal development of male sexual characteristics in women and children

    ATRS' VIBEX QuickShot auto injector emphasizes enhanced performance on the attributes contributing most to patients successfully controlling their testosterone deficiency - reliable and consistent blood levels, ease and speed of self-administration, comfort and discretion.

    According to published data, 2013 U.S. sales of testosterone replacement therapies were approximately $2.8 billion dollars with prescriptions on average growing more than 20% annually.

    http://static.cdn-seekingalpha.com/uploads/2014/2/20/saupload_atrs_chart2.png

    ATRS focuses on self-administered parenteral pharmaceutical products and topical gel-based medicines.

    More about Antares Pharma Inc. (ATRS) at www.antarespharma.com

    **

    http://static.cdn-seekingalpha.com/uploads/2014/2/20/saupload_powr.jpg PowerSecure International, Inc. (NYSE:POWR)

    POWR reported that it has been awarded approximately $20 million of new business.

    The new business awards include approximately $7 million of new turnkey distributed generation business, approximately $7 million of additional utility infrastructure business and approximately $6 million in new energy efficiency sales.

    http://static.cdn-seekingalpha.com/uploads/2014/2/20/saupload_powr_chart.png

    POWR is a leading provider of utility and energy technologies to electric utilities, and their industrial, institutional and commercial customers.

    More about PowerSecure International, Inc. (POWR) at www.powersecure.com.

    **

    Read Full Disclaimer at www.pennyomega.com/disclaimer

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Stocks: ATRS, POWR
Back To Mike Zaman's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.